Medullary thyroid carcinoma - Update and present management controversies

Annals of the Royal College of Surgeons of England

Volumn 88, Issue 5, 2006, Pages 433-438

  Al Rawi, Mahir ^a   Wheeler, Malcolm H ^a,b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Current therapy; Genetic; Medullary thyroid carcinoma; Sporadic

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; DNA; PROTEIN RET; RADIOACTIVE IODINE;

CALCITONIN BLOOD LEVEL; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CERVICAL LYMPH NODE; DISEASE ASSOCIATION; DNA DETERMINATION; ECHOGRAPHY; FAMILIAL CANCER; GENETIC ANALYSIS; HEAD AND NECK SURGERY; HUMAN; HYPERPARATHYROIDISM; IMAGING SYSTEM; LAPAROSCOPY; LIVER BIOPSY; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MEDLINE; MINIMAL RESIDUAL DISEASE; MISSENSE MUTATION; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; REVIEW; SIPPLE SYNDROME; SURVIVAL TIME; THYROID MEDULLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

CARCINOMA, MEDULLARY; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; REOPERATION; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 33748709257     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588406X117043     Document Type: Review

References (33)

1. Jaquet AJ. Ein fall von metastasierenden amyloidtumoren (lymphosarcoma). Virchow's Arch A Pathol Anat 1906; 185: 251-67
2. Hazard JB, Hawk WA, Crile GJ. Medullary (solid) carcinoma of the thyroid. A clinicopathologic entity. J Clin Endocrinol Metab 1959; 19: 152-61.
3. Williams ED. Diarrhoea and thyroid carcinoma. Proc R Soc Med 1966; 59: 602-3.
4. Williams ED. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1966; 19: 114-8.
5. Mure A, Gicquel C, Abdelmoumene N, Tenenbaum F, Francese C, Travagli JP et al. Cushing's syndrome in medullary thyroid carcinoma. J Endocrinol Invest 1995; 18: 180-5.
6. Roberts 2nd LJ, Hubbard WC, Bloomgarden ZT, Bertagna XY, McKenna TJ, Rabinowitz D et al. Prostaglandins: role in the humoral manifestations of medullary carcinoma of the thyroid and inhibition by somatostatin. Trans Assoc Am Phys 1979; 92: 286-91.
7. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 1997; 103: 60-9.
8. Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J Surg 2000; 24: 952-6.
9. Mulligan CM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-60.
10. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 7: 851-6.
11. Moley JF, Albinson C. Medullary thyroid carcinoma and the multiple endocrine neoplasia type 2 syndromes. In: Doherty GM, Skögseid B. (eds) Surgical Endocrinology. Philadelphia, PA: Lippincott Williams and Wilkins, 2001; 541.
12. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994; 6: 70.
13. Musholt TJ, Hanack J, Brehm C, von Wasielewski R, Musholt PB. Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression - World J Surg 2005; 29: 472-482.
14. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Kuma S et al. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma. World J Surg 2000; 24: 1367-72.
15. Miyauchi A, Matsuzuka F, Hirai K, Yokozawa T, Kobayashi K, Ito Y et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 2002; 26: 1023-8.
16. Raffel A, Cupisti K, Krausch M, Wolf A, Schulte K-M, Röher H-D. Incidentally found medullary thyroid cancer: treatment rationale for small tumours. World J Surg 2004; 28: 397-401.
17. Sizemore GW, Carney JA, Heath H. Epidemiology of medullary carcinoma of the thyroid gland: a 5 year experience (1971-1976). Surg Clin North Am 1977; 57: 633-45.
18. Niccoli P, Wion-Barbot N, Caron P, Henry JF, deMicco C, Saint, Andre JP et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients - The French Medullary Study Group. J Clin Endocrinol Metab 1997; 82: 338-41.
19. Gibelin H, Essique D, Jones C, Levillain P, Maréchaud R, Kraimps J-L. Increased calcitonin level in thyroid nodules without medullary carcinoma. Br J Surg 2005; 92: 574-8.
20. O'Riordain DS, O'Brien T, Weaver AL, Gharib H, Hay ID, Grant CS et al. Medullary thyroid carcinoma in multiple endocrine neoplasia type 2A and 2B. Surgery 1994; 116: 1017-23.
21. Moley JF, DeBenedetti M. Patterns of nodal metastases in palpable medullary thyroid carcinoma. Ann Surg 1999; 229: 880-8.
22. Wells Jr SA, Chi DD, Toshima K, Dehner LP, Coffin CM, De Nenedetti MK et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994; 220: 237-50.
23. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002; 89: 1073-5.
24. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998; 22: 562-8.
25. Dralle H, Damm I, Scheumann GFW, Kotzerke J, Kupsch E, Geerlings H et al. Compartment-orientated microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994; 24: 112-21.
26. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninaemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990; 212: 395-401.
27. Tisell L, Hansson G, Jansson S, Salander H. Re-operation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986; 99: 60-6.
28. Moley JF, Wells SA, Dilley WG, Tisell EE. Re-operation for recurrent or persistent medullary thyroid carcinoma. Surgery 1993; 114: 1090-5.
29. Moley JF, Dilley W, DeBenedetti M. Improved results of cervical re-operation for medullary thyroid carcinoma. Ann Surg 1997; 225: 734-43.
30. Gimm O, Dralle H. Re-operation in metastasizing medullary thyroid carcinoma: is a tumour stage-orientated approach justified? Surgery 1997; 122: 1124-30.
31. Lips C, Landsvater R, Hoppener J, Geerdink RA, Blijham G, Jansen-Schillhorn van Veen JM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplesia. N Engl J Med 1994; 331: 828-35.
32. Wells SA, Skinner MA. Prophylactic thyroidectomy based on direct genetic testing in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998; 106: 29-34.
33. Dralle H, Gimm O, Simon D, Frank-Raue K, Görtz G, Niederle B et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998; 22: 744-51.